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Background: HS219 (40 mg chitosan-loaded chewing gum) is designed to bind salivary phosphorus as an add-on
to available phosphorus binders. We performed a randomized, placebo-controlled, double-blind study to evaluate
the efficacy and safety of HS219 in hemodialysis (HD) patients with hyperphosphatemia as an add-on to
phosphorus binders.
Methods: Sixty-eight HD patients who were maintained on calcium carbonate (n = 33) or sevelamer
hydrochloride (n = 35) were enrolled. The primary end point was a change in serum phosphorus levels. Secondary
end points included changes in levels of salivary phosphorus, serum calcium, parathyroid hormone (PTH), and
intact fibroblast growth factor (iFGF) 23.
Results: Sixty-three patients chewed either HS219 (n = 35) or placebo (n = 28) for 30 min, three times a day, for
3 weeks. HS219 was well tolerated and safe. However, HS219 was not superior to placebo with additional
reduction of serum phosphorus with respect to phosphorus binders at the end of the chewing period. There were
no significant effects of HS219 on reduction of salivary phosphorus, serum calcium, iPTH, or iFGF23 levels.
Conclusions: The chitosan-loaded chewing gum HS219 does not affect serum and salivary phosphorus levels in
Japanese HD patients with hyperphosphatemia. Our findings do not support previous findings that 20 mg of
chitosan-loaded chewing gum reduces serum and salivary phosphorus levels.
Trail registration: ClinicalTrials.gov NCT01039428, 24 December, 2009.
Keywords: Chewing gum, Chitosan, Clinical trial, Hemodialysis, Hyperphosphatemia, Phosphorus bindersBackground
Cardiovascular disease is the most common cause of death
in patients with end-stage renal disease (ESRD) who are
undergoing hemodialysis (HD) [1]. Increased levels of
serum phosphorus in HD patients are associated with an
increased incidence and mortality of cardiovascular diseases
[2]. However, HD and restriction of dietary phosphorus re-
sult in insufficient control of serum phosphorus [3]. Oral* Correspondence: akizawa@med.showa-u.ac.jp
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unless otherwise stated.phosphorus binders, such as calcium carbonate, sevelamer
hydrochloride, lanthanum carbonate, and bixalomer, are
currently used for the treatment of ESRD patients with
hyperphosphatemia in Japan [4]. These phosphorus binders
primarily trap dietary intake of phosphorus in the gut by an
ion exchange reaction. Therefore, patients often have to
take many phosphorus binder pills three times daily with
meal, and this is associated with a risk of gastrointestinal
symptoms and decrease adherence [5].
Notably, salivary phosphorus levels are higher than those
in serum, particularly in patients with chronic kidney dis-
ease [6] and ESRD [7]. It is reported that the salivary flowl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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adults [8,9]. The daily saliva production ranges from 500
to 1500 mL [10]. Therefore, salivary phosphorus is an al-
ternate source of phosphorus which should not be ig-
nored, and could be a novel target for a novel phosphorus
restriction.
Chitosan is a non-toxic natural fiber prepared by dea-
cetylation of chitin from the shells of crustaceans, such
as crabs and shrimps, and is used worldwide as a dietary
supplement [11-13] and food additive [14]. The chemical
structure of chitosan is a beta-1,4-linked polymer of D-
glucosamine and its amino residue can stoichiometric-
ally bind to phosphorus under physiological conditions.
HS219 is a three-layer chewing gum containing 40 mg
of chitosan, which is designed to trap salivary phosphorus
in the mouth. Savica et al. [15] reported that chewing a
chitosan (20 mg)-loaded chewing gum for 60 min in fast-
ing conditions twice a day for 2 weeks dramatically re-
duced salivary and serum phosphorus levels in HD
patients with hyperphosphatemia as per serum phos-
phorus levels ≥6 mg/dl, despite treatment with sevelamer
hydrochloride. However, this study was an open-label, sin-
gle center clinical study in only 13 HD patients.
Therefore, we designed a multi-center, randomized,
placebo-controlled, double-blind study to evaluate the effi-
cacy and safety of HS219 when chewed for 30 min, 3 times
a day for 3 weeks in HD patients with hyperphosphatemia
whose serum phosphorus levels were not well controlled
with either calcium carbonate or sevelamer hydrochloride.
Methods
Study design
This was a multi-center, randomized, double-blind, placebo-
controlled, parallel-group, comparative study in Japan. ESRD
patients with hyperphosphatemia who were poorly con-
trolled by phosphorus binders were recruited from 11 study
sites in Japan from December 2009 to June 2010. The proto-
col and informed consent form were reviewed and approved
by one central Ethics Committee: Ethics Committee of the
Japanese Red Cross Koga Hospital, Koga, Ibaragi, Japan and
four site-based Ethics Committee/Institutional Review
Boards: Ethics Committee of the Japanese Red Cross Suwa
Hospital, Suwa, Nagano, Institutional Review Board of the
Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaragi, Ethics
Committee of the Asahi General Hospital, Asahi, Chiba, and
Ethics Committee of the JA Toride Medical Center, Toride,
Ibaragi, Japan. All of the patients gave written informed con-
sent before the initiation of any study-specific procedure.
This study was carried out in accordance with the ethical
principles of the Declaration of Helsinki and the Ethical
Guidelines for Clinical Studies issued by the Ministry of
Health, Labour and Welfare of Japan in 2003. This study
was registered on December 24, 2009 as NCT01039428 at
the ClinicalTrials.gov database.Patients
This study enrolled men and women with ESRD. They
were ≥ 20 years of age and had been undergoing regular
hemodialysis for three times a week for at least 12 weeks.
The rate of urea reduction was controlled at > 60% for at
least 4 weeks before they provided informed consent. They
were maintained on either calcium carbonate or sevelamer
hydrochloride alone with a stable regimen with respect to
dose and frequency for at least 4 weeks before and
throughout the study. The patients were required to
undergo dietary phosphorus restriction throughout the
study. The major inclusion criteria required a mean value
of the latest three serum phosphorus levels of > 5.5 mg/dl
and < 9.0 mg/dl, and a rate of salivary flow ≥ 1 g/2 min
by the Saxon test [16]. The inclusion criteria of salivary
flow rate was set based on a feasibility study conducted
in Japanese HD patients (data not shown in this article)
that indicated the number of the patients whose salivary
flow rate > 2 g/2 min by the Saxon test were limited, and
even a patient between 1 and 2 g/2 min were found to be
able to chew the gum for 30 min. Patients who used active
vitamin D derivatives and/or cinacalcet were required to
have maintained a stable dosage and frequency for ≥ 4 weeks
before and throughout the study. Patients were excluded
from the study for the following reasons: they were being
treated with blood purification therapy other than HD; they
had a severe gastrointestinal motility disorder; they had any
other clinically significant unusual medical conditions, such
as malignancy or severe cardiovascular disorders; they had
a history of chitosan, chitin, and/or shellfish allergy; and
they were not able to chew the chewing gum. HD condi-
tions including the dialysis time within 10% variation, blood
flow rate within 10% variation, dialyzer, and dialysate were
required to be maintained during the study.
Interventions
The eligible patients were first stratified within each treat-
ment arm by type of phosphorus binder (calcium carbonate
or sevelamer hydrochloride), and were then randomized in
a 1:1 ratio to receive HS219 or placebo chewing gum by
computer-generated randomization with sequencing in
blocks of four. Patients chewed either HS219 or placebo
chewing gum three times a day while fasting (i.e., between
meals) for 30 min for 3 weeks. A 3-week follow-up period
for safety evaluation and efficacy recovery concluded the
controlled study. All of the patients were treated and con-
tinued using the same single phosphorus binder (dosage
and frequency) used at the time of screening, during and
after the study. The patients’ adherence with the treatment,
compliance with their phosphorus binder, and phosphorus-
restricted diet throughout the study, including the follow-
up period, were checked weekly by diary entries made by
the patients. The patients were instructed how to chew the
chewing gum before starting the study.
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6) before the first dialysis of the week (Monday or Tues-
day) to determine serum phosphorus, calcium, and albu-
min levels. iPTH, whole PTH, and iFGF 23 were also
measured at three points throughout the study as follows:
before the treatment (week 0), at the end of the treatment
(week 3), and at the end of the follow-up period (week 6).
Whole saliva samples were collected using Salivette cotton
(Sarstedt Ltd., Nümbrecht, Germany) before the first dia-
lysis of the week at each patient’s visit. All participants
were instructed not to eat, drink, or chew gum for at least
60 min before saliva collection.
Salivary phosphorus levels were determined by spectro-
scopic assay using a Biochain Phosphorus assay kit (CA,
USA) at Gifu Pharmaceutical University. Serum phos-
phorus levels were analyzed at each institution. Serum
levels of whole PTH and iPTH were analyzed by immu-
noradiometric assay and electrochemiluminescence im-
munoassay, respectively, at SRL Inc., Tokyo, Japan. iFGF
23 were determined using an FGF ELISA kit (Kainos
Laboratories Inc., Tokyo, Japan) at a centralized laboratory.
Chewing gum
HS219 is a three-layered tablet type of chewing gum,
which contains 40 mg of food-grade medium-viscosity
chitosan in the inner gum core layer. HS219 and its
matching placebo chewing gum were provided by CM&D
Pharma Limited, London, UK. Labeling and distribution
were handled by Advance CRO Co., Ltd., Tokyo, Japan.
Criteria for evaluation
The primary efficacy end point was changes in serum
phosphorus levels from baseline to the end of the chew-
ing period. Secondary end points included the ratio of
patients whose reduction in serum phosphorus levels
was ≥ 1.5 mg/dl from baseline to the end of the chewing
period, the rate of patients whose serum phosphorus levels
at the end of the chewing period were ≥ 3.5 mg/dl and <
5.5 mg/dl, and changes with time in levels of serum and
salivary phosphorus, and serum calcium, phosphorus
products (Ca × P), iPTH, whole PTH, and iFGF23. Ad-
verse events, clinical laboratory assessments, and physical
examination data were collected for evaluation of safety.
Statistical analysis
The sample size in each treatment group was 26. There-
fore, a two-group, one-sided U-test at a 2.5% significance
level had 80% power to reject the null hypothesis that
the difference in mean serum phosphorus levels between
the HS219 and placebo groups at the end of treatment
is <1.5 mg/dl. We assumed that there would be a reduc-
tion in 2.35 mg/dl of serum phosphorus with chewing
HS219 according to Savica et al.’s study [15]. This was
based on the assumption that the expected difference inthe mean serum phosphorus levels between the chitosan
group and the placebo group is 1.5 mg/dl, and the com-
mon standard deviation is 1.8 mg/dl [15]. To allow for a
dropout rate of approximately 15% for the per-protocol
analysis, a total sample size of 64 was appropriate.
Changes in serum phosphorus levels in each treatment
group between baseline and at the end of chewing were
compared using the Mann–Whitney U test, and changes
were analyzed using analysis of covariance with treatment
as a factor and the baseline value as the covariate. The last
available (i.e., immediately after the chewing period) serum
phosphorus level was used in the analysis of patients who
discontinued treatment before the end of the experimental
period. Data on the rates were compared using Fisher’s
exact test and odds ratios. The 95% confidence interval (CI)
for the estimated mean difference between mean levels of
serum phosphorus, salivary phosphorus, serum calcium
and serum phosphorus products (Ca × P) between the
HS219 and placebo groups were determined in each week.
Safety data were compared using Fisher’s exact test.
All analyses were performed using the “R Ver. 2.10.1”
software package [17].
Results
Patients’ characteristics and disposition
Written informed consents were obtained from 71 patients,
but two withdrew their consent and one failed to meet the
salivary flow rate ≥ 1 g/2 min by the Saxon test before re-
lease of the randomization code. Sixty-eight patients (33
were using calcium carbonate and 35 were using sevelamer
hydrochloride) were randomized, but five patients (n = 4,
calcium carbonate; n = 1, sevelamer hydrochloride) with-
drew from the study. Ineligibility of these patients was re-
vealed after release of the randomization code: three
patients failed to meet the eligibility criteria and two pa-
tients withdrew their consent. Sixty-three patients (n = 35,
HS219; n = 28, placebo) chewed at least one tablet of chew-
ing gum and were included in the intent-to-treat popula-
tion for the analysis of efficacy and safety. Sixty-one
patients (n = 33, HS219; n = 28, placebo) completed the 3-
week treatment phase. One patients was not included be-
cause of withdrawal of consent and one was not included
for failure to comply with the study protocol because of a
change in dialyzer during the treatment phase.
The demographic and clinical characteristics of the pa-
tient population were well balanced between the HS219
arm and placebo arm (Figure 1 and Table 1).
Efficacy of treatment
Changes in mean serum phosphorus levels from baseline
to the end of treatment in the HS219 and placebo groups
were −0.3 ± 1.2 mg/dl and −0.2 ± 1.2, respectively, with no








HS219 HS219 Placebo Placebo
with CaCO with sevelamer with CaCO with sevelamer3 3
n = 19 n = 18 n = 14 n = 17
Discontinued:   n = 1 Discontinued:   n = 1 Discontinued:   n = 3
Protocol violation: 1 Consent withdrawn: 1 Protocol violation: 2
Consent withdrawn: 1
SAS/FAS SAS/FAS SAS/FAS SAS/FAS
n = 18 n = 17 n = 11 n = 17
Discontinued:   n = 2
Protocol violation: 1
Consent withdrawn :1
Completed Completed Completed Completed
n = 18 n = 15 n = 11 n = 17
Figure 1 Flow chart of patients enrolled in the study. The following populations were defined. (i) The full analysis set (FAS) included a subset
of patients who subsequently received chewing gum and had any of the variables for efficacy measured. (ii) The safety analysis set (SAF) included
a subset of patients who received one or more doses of the chewing gum.
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was reduced ≥ 1.5 mg/dl with chewing gum treatment was
7/35 (20%) in the HS219 group and 2/28 (7%) in the pla-
cebo group (p = 0.28). Lowering of serum phosphorus levels
to achieve the targeted level of ≥ 3.5 mg/dl and < 5.5 mg/dl
phosphorus (19) occurred in 8/31 (26%) patients in the
HS219 group and in 2/23 (9%) patients in the placebo
group (p = 0.16), respectively.
HS219 had no overall significant effect on changes with
time in serum or salivary phosphorus, or serum calcium,
Ca x P products, iPTH, or iFGF23 levels as secondary end
points (Table 3).
Safety
The safety population included all of the patients who
chewed at least one chewing gum (HS 219 or placebo)
during the study period. Thirty-one adverse events were
recorded in 21/63 patients. The overall incidence of ad-
verse events was 13/35 (37%) in the HS219 group and 8/
28 (29%) in the placebo group (p = 0.593). Adverse events
not ruled out in relation to chewing gum were two in 63
patients; dizziness was observed with HS219 and loss of a
tooth filling was observed with the placebo. No clinically
significant abnormalities in laboratory values or vital signs
were reported.
Discussion
Salivary phosphorus is an alternative source of endogen-
ous phosphorus, which is secreted into the mouth andthen reabsorbed via the gut [6,7]. HS219 is a chitosan-
loaded chewing gum, which is designed to bind salivary
inorganic phosphorus directly in the mouth. HS219 was
developed as a supplementary food for chronic kidney
disease and ESRD patients with hyperphosphatemia who
are treated with phosphorus binders.
Savica et al. reported an effect of chitosan (20 mg)-loaded
chewing gum on serum and salivary phosphorus levels in
HD patients with hyperphosphatemia who did not respond
to a daily 3.2-4.8 g dose of sevelamer hydrochloride for
6 months and whose serum phosphorus levels were 7.6 ±
0.9 mg/dl [15]. They found that only 1-h chewing twice a
day for 2 weeks dramatically reduced salivary and serum
phosphorus levels by 55% (73.2 ± 19.2 to 33.2 ± 6.5 mg/dl,
p < 0.00001) and 31% (7.6 ± 0.9 to 5.3 ± 0.9 mg/dl, p <
0.00001), respectively.
We aimed to confirm this surprising efficacy in Japanese
HD patients by a randomized, placebo-controlled, double
blind study. We considered that a daily 40 mg dose of chi-
tosan for 2 weeks of treatment was too low to explain a re-
duction in salivary and serum phosphorus levels compared
with the daily dose of calcium carbonate (3 g/day) and seve-
lamer hydrochloride (3–6 g/day). No information on the
dose–response of chitosan was available in the literature
[15]. Therefore, we investigated why chitosan-loaded chew-
ing gum showed add-on effects to sevelamer hydrochloride
based on quantitative analysis of Savica et al.’s report [15].
First, we increased the chitosan content in a chewing
gum as much as possible. However, 40 mg of chitosan was
Table 1 Patient characteristics
HS219 n = 35 Placebo n = 28 p-value
Sex
Male 24 (68.6%) 19 (67.9%)
1†
Female 11 (31.4%) 9 (32.1%)
Age (years)
57 ± 11. 56 ± 11
0.585‡
(34, 59, 79) (30, 57.5, 76 )
Weight before HD (kg)
59.7 ± 11.0 62.0 ± 16.4
0.861‡
(40.8, 59.7, 86.7) (39.3, 58.3, 120.4)
Primary disease
Chronic glomerulonephritis 20 19
0.204‡
Diabetic nephropathy 8 6
Nephrosclerosis 2 2
Polycystic kidney disease 0 1
Others 5 0
Duration of dialysis (year)
8.7 ± 6.8 8.7 ± 6.1
0.706‡
(0.8, 7.3, 32.9) (0.5, 8.2, 24.1)
Hemodialysis time (hr)
4.2 ± 0.4 4.1 ± 0.3
0.978‡
(3.5, 4, 5) (3, 4, 5)
Kt/V
1.43 ± 0.24 1.41 ± 0.22
0.718‡
(1.09, 1.37, 2.07) (1.10, 1.415, 1.87)
Salivary flow rate (g/2 min)
3.91 ± 2.24 3.76 ± 1.69
0.986‡
(1.02, 3.56, 10.3) (1.46, 3.4, 7.42)
Phosphate binder
Calcium carbonate 18 11
0.447‡
Sevelamer 17 17
Daily dose of phosphate binder
Calcium carbonate (g/d)
2.4 ± 1.3 2.8 ± 1.5
0.548‡
(1, 2, 6) (1, 3, 6)
Sevelamer hydrochloride (g/d)
2.7 ± 1.4 3.0 ± 2.1
0.952‡
(0.75, 3, 5.25) (0.75, 3, 7.5)
Age, weight before HD, duration of dialysis, hemodialysis time, Kt/V, salivary flow rate, and daily dose of phosphate binder were presented by mean ± SD (min, median, max).
†Fisher’s exact test, ‡U-test.
Table 2 Changes in serum phosphorus level from baseline at week 3
Treatment Serum phosphorus Mean ± SD (mg/dl)
U-testPhosphate binder n Baseline End of treatment Change from baseline
Overall
HS219 35 6.7 ± 1.0 6.4 ± 1.3 −0.3 ± 1.2
p = 0.652
Placebo 28 6.5 ± 1.3 6.3 ± 1.3 −0.2 ± 1.2
CaCO3
HS219 18 6.6 ± 1.0 6.1 ± 1.2 −0.4 ± 1.3
p = 0.799
Placebo 11 6.3 ± 1.3 6.1 ± 1.0 −0.2 ± 0.9
Sevelamer
HS219 17 6.7 ± 1.1 6.6 ± 1.5 −0.1 ± 1.0
p = 0.568
Placebo 17 6.6 ± 1.3 6.4 ± 1.5 −0.2 ± 1.4
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Table 3 Salivary phosphorus, serum calcium, serum Ca x P, serum iPHT, serum whole PTH and iFGF23 levels at
baseline and week 3
Parameter Period
HS219 Placebo Mean
differencea 95% CI U testn Mean ± SD n Mean ± SD
Serum phosphorus (mg/dl)
Baseline 35 6.7 ± 1.0 28 6.5 ± 1.3 0.2 −0.5 ~ 0.8 P = 0.677
Week 3 32 6.4 ± 1.4 28 6.3 ± 1.3 0.1 −0.6 ~ 0.8 P = 0.900
Salivary phosphorus (mg/dl)
Baseline 35 24.0 ± 10.4 28 23.7 ± 8.9 0.2 −4.6 ~ 5.1 P = 0.964
Week 3 32 22.3 ± 8.0 28 21.5 ± 9.0 0.8 −3.6 ~ 5.2 P = 0.656
Serum Ca (mg/dl)
Baseline 35 9.3 ± 0.7 28 9.2 ± 0.6 0.2 −0.1 ~ 0.5 P = 0.299
Week 3 33 9.4 ± 0.7 28 9.1 ± 0.6 0.2 −0.1 ~ 0.6 P = 0.149
Serum Ca x P (mg2/dl2)
Baseline 35 62.0 ± 10.3 28 59.3 ± 11.1 2.7 −2.8 ~ 8.2 P = 0.490
Week 3 33 59.9 ± 13.9 28 57.2 ± 11.3 2.7 −3.8 ~ 9.1 P = 0.520
iPTH (pg/ml)
Baseline 35 233 ± 148 28 233 ± 156 1 −77 ~ 78 P = 0.760
Week 3 33 207 ± 141 28 251 ± 184 −45 −130 ~ 41 P = 0.511
whole PTH (pg/ml)
Baseline 35 133 ± 89 28 137 ± 97 −4 −51 ~ 44 P = 0.899
Week 3 33 118 ± 92 28 140 ± 102 −22 −72 ~ 28 P = 0.511
iFGF23 (log10 pg/ml)
Baseline 35 4.1 ± 0.5 28 4.0 ± 0.6 0.1 −0.2 ~ 0.3 P = 0.736
Week 3 33 4.0 ± 0.5 28 4.0 ± 0.5 0.0 −0.3 ~ 0.3 P = 0.960
aMean difference between HS219 and placebo of group at baseline or week 3.
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gum. We increased the chewing times from two to three
times a day, and designed the treatment period in our study
for 3 weeks. The daily chitosan dose was 120 mg and the
total amount of chitosan chewed in our study was 2520 mg.
Our dose was 3 times higher than the daily dose and 4.5
times higher than the total dose compared with those in
Savica et al.’s study (40 mg/day and 560 mg/study).
Chitosan is a polymer of glucosamine, which contains
one amino residue. The molecular weight of this glu-
cosamine unit is 161.2 (glucosamine - H2O) and the
daily amount of 120 mg chitosan is 0.750 mmol. As well
as an ion-exchange reaction, we expected ester forma-
tion between the two hydroxyl residues of glucosamine
and phosphorus as additional phosphorus-binding cap-
acities of chitosan [18]. The total number of phosphorus
binding sites of the glucosamine unit is three and the
total theoretical phosphorus binding capacity of 40 mg
of chitosan is 2.25 (0.75 × 3) mmol. The pKa values of
phosphate, 2.16, 7.21, and 12.32, indicate that mainly two
ionic forms exist at pH 7.4. Therefore, the actual binding
capacity under physiological conditions should be less
than that calculated above. However, even if 2.25 mmol of
chitosan would participates in binding stoichiometrically
to phosphorus, it is only 0.08 equivalent to the daily dose
(3 g, 30 mmol) of calcium carbonate. There is a report that
oral administration of 1350 mg/day (8 mmol) of chitosan
for 12 weeks in HD patients reduced serum total choles-
terol level significantly, but did not affect serum phos-
phorus levels [19]. This suggests that chitosan itself would
not be a single player as a phosphorus binder andadditional effects are likely to be involved in chitosan-
loaded chewing gum.
Second, we expected an add-on effect of chitosan to
phosphorus binders. The lack of dose of phosphorus
binders, wherein the required dose cannot be adminis-
tered because of their side effects, would be covered by
HS219. However, we should know the expected add-on
effect might be less than 10% and its contribution would
be limited.
Third, we expected an chewing effect on salivary flow
rate. Chewing gum is reported to stimulate salivary flow
rate in healthy adults [20,21] and in HD patients [22,23].
Increased salivary flow increases the gut fluid volume and
solid (phosphorus binder)-liquid (phosphorus) reaction
would be accelerated and result increase the yield of phos-
phorus trapping. We considered that a chewing time of
30 min was sufficient to compare with the 1-h chewing
time in Savica et al.’s study [15]. This is because the peak
of chewing-stimulated salivary flow rate has been reported
to be approximately 6 ml/min in the first minute and de-
creases to a plateau of approximately 1 ml/min across the
next 15 min in healthy adults [24]. With regard to salivary
flow rate in HD patients, two different observations have
been made; one is that there was no difference compared
with healthy controls [25,26] and the other was that saliv-
ary flow rate was less than that in healthy controls [9,27].
We expected that the sum of these three hypotheses de-
scribed above could explain the rationale of the efficacy of
chitosan-loaded chewing gum. However, unfortunately, in
our study, the chitosan (40 mg)-loaded chewing gum
HS219 did not show any effect of reduction in salivary and
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chitosan dose was still too low, and that neither an add-on
effect nor chewing effect of chitosan-loaded chewing gum
reflected in the clinical outcome. Furthermore, HS219 did
not result in any biological responses of serum Ca, Ca x
phosphorus products, iPTH, whole PTH, or FGF23 com-
pared with placebo. Block et al. reported similar negative
results of chitosan (20 mg)-loaded chewing gum by a ran-
domized, placebo-controlled, double-blind study in HD
patients [28]. In chronic kidney disease patients, chitosan
chewing gum reduced serum phosphorus levels by only
0.14-0.20 mg/dl [28]. These two independent randomized,
placebo-controlled, double-blind studies revealed a better
understanding of the lack of clinical benefits of chitosan-
loaded chewing gum in HD patients. The positive results
from the open-label, non-controlled study by Savica et al.
[15] were a result of biases, as commented by Oh and
Uribarri [29]. Our study suggests that there are pitfalls in
non-randomized, open-label clinical studies.
Although Savica et al. [15] reported a good association
between salivary and serum phosphorus levels, we did not
observe any association between these variables at baseline
(n = 63, r = 0.136, p = 0.287). However, mean salivary phos-
phorus levels in HD patients in our study were approxi-
mately 3.5 times higher than those of serum levels. Daily
production of saliva in healthy subjects is reported to be
500–1000 ml [10]. Salivary flow rates of HD patients en-
rolled in our study were higher than 3.5 g/2 min by the
Saxon test, which are similar to those of normal subjects.
This finding indicates that the supply of phosphorus from
saliva to the gut might be 118–240 mg/day, which is a
considerable amount, as well as that from food. Although
HS219 did not show any efficacy in patients with hyper-
phosphatemia, salivary phosphorus still remains a potent
and novel target of phosphorus restriction.
FGF23 is one of the most recently identified phosphoric
factors, which regulate mineral and vitamin D metabolism
[30]. Serum iFGF23 levels in HD patients are elevated over
a wide range [31], and FGF23 levels in our study were ex-
tremely elevated. We observed a good correlation between
serum phosphorus and iFGF23 levels at baseline, and be-
tween changes in serum phosphorus and FGF23 levels. The
lack of effect of HS219 on serum FGF23 levels provides
additional evidence that HS219 does not affect phosphorus
metabolism in HD patients with hyperphosphatemia.Conclusions
Our randomized, placebo-controlled, double-blind study
shows that HS219 (chitosan-loaded chewing gum) did
not show any add-on effect on salivary and serum phos-
phorus levels in HD patients with hyperphosphatemia
who are treated with either sevelamer hydrochloride or
calcium carbonate.Abbreviations
ESRD: End-stage renal disease; HD: Hemodialysis; iPTH: intact parathyroid
hormone; iFGF23: intact fibroblast growth factor 23.
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